Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1137 | 2020 |
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, ... The Lancet 390 (10094), 555-566, 2017 | 569 | 2017 |
Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a … MCA Palanca-Wessels, M Czuczman, G Salles, S Assouline, LH Sehn, ... The Lancet Oncology 16 (6), 704-715, 2015 | 334 | 2015 |
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression ED Jacobsen, JP Sharman, Y Oki, RH Advani, JN Winter, CM Bello, ... Blood, The Journal of the American Society of Hematology 125 (9), 1394-1402, 2015 | 321 | 2015 |
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes M Pfeifer, B Zheng, T Erdmann, H Koeppen, R McCord, M Grau, A Staiger, ... Leukemia 29 (7), 1578-1586, 2015 | 168 | 2015 |
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older A Forero-Torres, B Holkova, J Goldschmidt, R Chen, G Olsen, RV Boccia, ... Blood, The Journal of the American Society of Hematology 126 (26), 2798-2804, 2015 | 152 | 2015 |
Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities MC Palanca-Wessels, MT Barrett, PC Galipeau, KL Rohrer, BJ Reid, ... Gastroenterology 114 (2), 295-304, 1998 | 103 | 1998 |
Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett’s esophagus MT Barrett, D Pritchard, C Palanca-Wessels, J Anderson, BJ Reid, ... Cancer research 63 (14), 4211-4217, 2003 | 91 | 2003 |
Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model MCA Palanca-Wessels, A Klingelhutz, BJ Reid, TH Norwood, KE Opheim, ... Carcinogenesis 24 (7), 1183-1190, 2003 | 76 | 2003 |
Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells MC Palanca-Wessels, AJ Convertine, R Cutler-Strom, GC Booth, F Lee, ... Molecular Therapy 19 (8), 1529-1537, 2011 | 74 | 2011 |
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry NL Bartlett, MR Smith, T Siddiqi, RH Advani, OA O’Connor, JP Sharman, ... Leukemia & Lymphoma 58 (7), 1607-1616, 2017 | 56 | 2017 |
Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells MC Palanca-Wessels, GC Booth, AJ Convertine, BB Lundy, GY Berguig, ... Oncotarget 7 (8), 9561, 2016 | 55 | 2016 |
Mutants of the Agrobacterium tumefaciens virA gene exhibiting acetosyringone-independent expression of the vir regulon RG Ankenbauer, EA Best, CA Palanca, EW Nester Mol. Plant-Microbe Interact 4, 400-406, 1991 | 55 | 1991 |
Advances in the treatment of hematologic malignancies using immunoconjugates MC Palanca-Wessels, OW Press Blood, The Journal of the American Society of Hematology 123 (15), 2293-2301, 2014 | 50 | 2014 |
Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody–polymer conjugate GY Berguig, AJ Convertine, J Shi, MC Palanca-Wessels, CL Duvall, ... Molecular pharmaceutics 9 (12), 3506-3514, 2012 | 46 | 2012 |
Intracellular delivery system for antibody–peptide drug conjugates GY Berguig, AJ Convertine, S Frayo, HB Kern, E Procko, D Roy, ... Molecular therapy 23 (5), 907-917, 2015 | 43 | 2015 |
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis YH Kim, HM Prince, S Whittaker, SM Horwitz, M Duvic, O Bechter, ... European Journal of Cancer 148, 411-421, 2021 | 38 | 2021 |
Improving the efficacy of radioimmunotherapy for non‐Hodgkin lymphomas MCA Palanca‐Wessels, OW Press Cancer 116 (S4), 1126-1133, 2010 | 36 | 2010 |
MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress). JH Strickler, K Ng, A Cercek, C Fountzilas, FA Sanchez, JM Hubbard, ... Journal of Clinical Oncology 39 (3_suppl), TPS153-TPS153, 2021 | 33 | 2021 |
Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies MC Ryan, MC Palanca-Wessels, B Schimpf, KA Gordon, H Kostner, ... Blood, The Journal of the American Society of Hematology 130 (18), 2018-2026, 2017 | 30 | 2017 |